GLP-1 Prior Authorization: Requirements and How to Appeal
If you have been trying to get your insurance to cover a GLP-1 medication, you have probably encountered prior authorization. It is the requirement that your prescriber submit clinical documentation to your insurer or pharmacy benefit manager before the insurance will approve and pay for the prescription. It is frustrating, it adds time, and it sometimes results in denial.
But it is not a personal judgment. It is a standard insurance process. And there are concrete steps you can take to improve the odds of approval, and clear appeal rights if the insurer says no.
Transformation Health is an independent guide, not a provider: we do not prescribe, sell medication, or bill insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Here is what you need to know.
What prior authorization actually is
Prior authorization (often abbreviated PA) is a utilization management process where your insurer or pharmacy benefit manager (PBM) requires your prescribing provider to submit clinical documentation justifying the prescription before they will approve coverage.
GLP-1 medications often go through prior authorization because they are expensive for plans to cover. Insurers use prior authorization to check that the medication is being prescribed for a use the plan covers and that the plan’s other requirements, such as trying other treatments first, have been met.
Prior authorization is not a judgment about your willpower or your commitment. It is a formulary management tool that plans use across many drug categories.
What GLP-1 prior authorization typically requires
Insurers do not have a single standardized PA form. Each plan has its own requirements, and requirements can differ between semaglutide and tirzepatide. Your plan’s prior authorization criteria for the specific drug are the document that settles what is needed. Many plans ask for these pieces of clinical information:
1. Documented body mass index (BMI) Plans often mirror the criteria for prescribing weight management medications: an adult BMI of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes.[1] Many plans want the BMI recorded by a clinician at a recent visit rather than self-reported.
2. List of comorbidities If your BMI is between 27 and 30, plans typically require documentation of at least one weight-related condition. Which conditions count is set by each plan’s criteria; high blood pressure and type 2 diabetes are common examples.[1]
3. Documentation of prior lifestyle intervention Many plans require evidence that you have already tried diet and exercise before they will cover medication. Some accept a note in the chart. Others require documented participation in a weight management or nutrition program for a period the policy specifies.
4. Confirmation of no contraindications The submission may need to show you do not have a contraindication listed on the drug’s label. The Wegovy and Zepbound labels list a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and known hypersensitivity to the drug or its ingredients as contraindications.[2][3] Pancreatitis is listed on both labels as a warning, not a contraindication; your prescriber decides how it applies to you.[2][3]
5. Sometimes: prior medication history Some plans ask whether you have previously tried other weight loss medications, such as phentermine or topiramate. This is not always required, but some plans want to see it.
6. Provider’s clinical notes The PA submission usually includes a brief clinical justification from the prescriber explaining why the medication is appropriate for your health situation. The diagnosis codes matter too: weight management requests typically pair an obesity code from the E66 series with a Z68 code that documents the BMI range. Our obesity ICD-10 codes guide lists them.
Who submits the prior authorization
Your prescribing provider’s office submits the PA, not you. But the office needs your insurance information to do so.
When you are prescribed a GLP-1 medication, the prescriber’s staff (or the pharmacy, when it flags that a PA is needed) starts the request with your insurer or PBM. Many offices handle prior authorizations routinely.
The insurer or PBM supplies the form, usually through an electronic system or fax. The office gathers the required documentation (usually from your medical record and any recent labs) and submits it.
How long does the process take
There is no single timeline. It depends on how quickly the prescriber’s office submits the request, how complete it is, and your plan. Expect days to weeks. Federal rules set outer limits for many plans:
Step 1: Provider submits the PA
The prescriber's office gathers documentation from your medical record, fills out the insurer's PA form, and submits it to the insurance company or PBM. How long this takes depends on the office and on whether anything is missing from your records.
Step 2: Initial insurer decision
The insurer reviews the PA submission. For employer plans covered by the federal claims rule, a decision on a request that needs approval in advance is due within 15 days, with one extension of up to 15 days allowed for matters beyond the plan's control, or within 72 hours if the request is urgent.[4] The insurer sends a decision to the prescriber's office and, often, directly to you.
Step 3a: If approved, the pharmacy fills the prescription
Once approved, the pharmacy fills your prescription. If the pharmacy has to order the medication or your dose is in short supply locally, that can add time.
Step 3b: If denied, the appeal process
If the insurer denies the PA, you have the right to appeal. HealthCare.gov says an internal appeal for a service you have not received yet must be completed within 30 days, and an urgent appeal within 4 business days.[5]
These are outer limits, not predictions. Your plan documents state the exact limits that apply to you, and state-regulated, Medicare, and Medicaid plans have their own rules.
Why prior authorization gets denied
First requests can be denied. Plans do not publish a single denial rate, and it varies by insurer and plan. Some denials come back for documentation gaps rather than because the person does not meet the plan’s criteria. Your denial notice should say which reason applies.
The most common denial reasons:
Missing or incomplete BMI documentation The insurer receives the PA but the documented BMI is missing, outdated, or unclear. If you have not had a recent visit with a recorded height and weight, the insurer may deny for insufficient evidence of a qualifying BMI.
Missing comorbidity documentation You have high blood pressure or diabetes, but these are not explicitly documented in the records submitted with the PA. The insurer denies because it cannot verify the condition from the paperwork.
No documentation of prior lifestyle intervention The plan requires evidence of diet and exercise attempts, but the submission did not include it.
Formulary exclusion Some plans have a categorical exclusion for weight management medications. If your plan excludes weight management GLP-1s entirely, the PA will be denied regardless of clinical appropriateness. (This is different from a clinical denial; the plan simply does not cover this use.)
Diagnosis that does not match a covered use The PA was submitted for weight management, but the plan only covers GLP-1s for other uses, such as type 2 diabetes or cardiovascular risk reduction. The insurer denies because the diagnosis does not match a covered indication.
The appeal process
If your initial PA is denied, you have the right to appeal. The process varies by plan and state, but this is the standard structure:
First-level appeal (Internal Review)
You (often with help from the prescriber’s office) ask the insurance company to take another look at the decision. HealthCare.gov says you must file an internal appeal within 180 days (6 months) of receiving the denial notice.[5]
A first-level appeal commonly includes:
- All original PA documentation
- Strengthened or clarified documentation addressing the reason for denial
- A letter from the prescriber explaining the clinical necessity
- When relevant, published trial data for the medication’s FDA-approved use (such as the STEP or SURMOUNT trials)
Decision time: within 30 days for a service you have not received yet, within 60 days for one you have already received, and within 4 business days for an urgent appeal.[5]
Second-level appeal
Some plans have a second internal level, often reviewed by a medical director. Your denial letter and plan documents say whether your plan has one and how long you have to file.
External Review
If the internal appeal is denied, you can, in many cases, ask for an independent external review by an outside reviewer rather than the insurer. HealthCare.gov says you must file within 4 months of the notice or final determination, the decision is due no later than 45 days after the request (72 hours or less for urgent cases), and your insurer is required by law to accept the external reviewer’s decision.[6] There is no charge under the HHS-administered process; other processes may charge a small fee, which HealthCare.gov says is capped.[6] In urgent situations, you may file an internal appeal and an external review request at the same time.[5]
Tips for improving your chances of PA approval
If you are about to start the prior authorization process, these steps can help:
1. Make sure your BMI is documented Ask your prescriber’s office whether a recent height, weight, and BMI are in your medical record. If not, a brief visit (telehealth is fine at many offices) can fix that before the PA is submitted.
2. Ensure all comorbidities are documented If you have high blood pressure, diabetes, sleep apnea, high cholesterol, or another weight-related condition, make sure it is in your medical record. If a diagnosis is missing, ask your prescriber whether it should be added before the PA is submitted.
3. Document prior lifestyle intervention If your plan requires evidence of diet and exercise attempts, share whatever accurate records you have, such as dietitian visits, records from a weight management program you joined, or notes from earlier appointments. Ask your prescriber to include an accurate summary of what you have tried in the PA submission.
4. Ask whether to include clinical literature Some offices attach published trial data supporting the medication’s FDA-approved use. For weight management, the main trials are STEP 1[7] (semaglutide) and SURMOUNT-1[8] (tirzepatide). Results vary, and trial results describe study participants, not a prediction for any individual.
5. Request expedited review if clinically justified If waiting could seriously harm your health, ask your prescriber to request an urgent (expedited) review. Plans must decide urgent requests on a faster timeline.[4][5]
When prior authorization will not work
There are situations where the PA process is unlikely to succeed, no matter how complete your documentation is.
Categorical formulary exclusion for weight management If your plan explicitly excludes GLP-1 medications for weight management (some plans do), prior authorization cannot override this. The medication is simply not covered for that use. Your options include: (1) asking whether the medication is covered for a different FDA-approved indication that applies to you, such as type 2 diabetes, (2) an exception request or appeal through your plan, though a plan-wide exclusion is hard to overturn, or (3) paying out of pocket.
No qualifying diagnosis in your plan’s covered indications If your plan only covers GLP-1s for type 2 diabetes or cardiovascular disease, and you do not have either condition, prior authorization based on weight management alone will not succeed.
Insurance lapse If your insurance lapses or changes during the PA process, the decision may no longer apply. You will need to resubmit with your new insurance information.
When cash-pay makes more sense
Some people decide that paying out of pocket is simpler than waiting on insurance, especially when the plan excludes weight management or an appeal has already failed. Whether it costs more or less depends on your plan and on what you choose.
Options to compare:
- Manufacturer self-pay programs for brand-name medications, which do not go through insurance
- Cash-pay telehealth programs, which do not bill insurance, so there is no prior authorization step. At most telehealth programs, a licensed provider still reviews your health history and decides whether a prescription is appropriate. Some prescribe brand-name medications; many prescribe compounded semaglutide or tirzepatide prepared by a compounding pharmacy.
Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. Our GLP-1 cost without insurance guide walks through what drives the price.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[9] Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency.
Transformation Health does not accept payment from providers. How we make money.
The trade-off is straightforward: out-of-pocket cost vs. the possibility (not certainty) of insurance coverage after a wait. You can also do both in parallel: keep the insurance request or appeal moving while you compare other options.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedFAQ
Q: How long does prior authorization for GLP-1 take?
A: It depends on your plan and how quickly the prescriber’s office submits the request, so expect days to weeks. For employer plans covered by the federal claims rule, a decision on a request that needs approval in advance is due within 15 days (the plan can extend once by up to 15 days), or within 72 hours if the request is urgent. If you are denied and appeal, HealthCare.gov says an internal appeal for a service you have not received yet must be decided within 30 days. Your plan documents state the exact limits that apply to you.
Q: What is the most common reason GLP-1 prior authorization is denied?
A: Plans do not publish one common reason, but denials often come back for documentation gaps: a BMI that is missing or out of date, conditions that are not in the submitted records, or no record of the steps the plan requires first, such as a lifestyle program. Others happen because the plan excludes weight management drugs or covers the medication only for a different diagnosis. The denial notice should say which reason applies.
Q: Should I appeal a GLP-1 PA denial?
A: It is often worth considering, especially when the denial points to missing or unclear documentation that your prescriber can supply. You generally have 180 days from the denial notice to file an internal appeal, and in many cases you can then ask for an independent external review. An appeal is less likely to help when the plan excludes weight management drugs as a category.
Q: What if my insurance categorically excludes weight management medications?
A: A categorical formulary exclusion for weight management drugs usually cannot be overridden through prior authorization. Options to look into include: (1) whether the medication is covered under a different FDA-approved indication that applies to you, such as type 2 diabetes, (2) an exception request or appeal through your plan, (3) a different plan at your next open enrollment, or (4) paying out of pocket through a manufacturer self-pay option or a cash-pay program.
Citations
[1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” Accessed 2026-10-16. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[2] Novo Nordisk. WEGOVY (semaglutide) prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[3] Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[4] 29 CFR 2560.503-1(f)(2) (claims procedure for employee benefit plans: urgent care and pre-service claim decision deadlines). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/29/2560.503-1
[5] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[6] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
[7] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
[8] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
[9] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, does not bill insurance, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency. Insurance and appeal information is general and does not represent your specific plan; confirm current details and deadlines with your plan. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.